BEGIN:VCALENDAR
VERSION:2.0
PRODID:https://murmitoyen.com/events/vanille/udem/
X-WR-TIMEZONE:America/Montreal
BEGIN:VEVENT
UID:69dae7999c6ae
DTSTAMP:20260411T203017
DTSTART:20180119T120000
SEQUENCE:0
TRANSP:OPAQUE
DTEND:20180119T130000
URL:https://murmitoyen.com/events/vanille/udem/detail/803419-can-personaliz
 ed-medicine-be-used-to-reduce-treatment-related-neurotoxicity-among-childr
 en-with-acute-lymphoblastic-leukemia
LOCATION:CHU Sainte-Justine\, 3175\, Chemin de la Côte-Sainte-Catherine\, 
 Montréal\, QC\, Canada\, H3T 1C5
SUMMARY:Can personalized medicine be used to reduce treatment-related neuro
 toxicity among children with acute lymphoblastic leukemia?
DESCRIPTION:Titre complet :
\nCan personalized medicine be used to reduce t
 reatment-related neurotoxicity among children with acut   Conférencier :P
 eter Cole\, MD (pour l'axe Maladies immunitaires et cancers)Professeur agr
 égé de pédiatrie\, Collège de médecine Albert Einstein et Hôpital po
 ur enfants de Montefiore.
\nRésumé : Drawing on a background in pediatri
 c oncology and the molecular pharmacology of chemotherapy\, my research fo
 cuses on reducing intellectual disabilities induced by anticancer therapy.
  My laboratory analyzes biomarkers in blood and cerebrospinal fluid\, coll
 ected from children treated for acute lymphoblastic leukemia\, to identify
  correlates and models predictive of treatment-related toxicities. Using a
 n animal model of chemotherapy-induced cognitive dysfunction\, we are defi
 ning the underlying pathophysiology and identifying protective interventio
 ns. In addition\, as vice Chair of the Children's Oncology Group Hodgkin L
 ymphoma Committee\, I have been actively involved in developing innovative
  therapeutic protocols for children and young adults with Hodgkin lymphoma
 .  
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/Montreal
X-LIC-LOCATION:America/Montreal
END:VTIMEZONE
END:VCALENDAR